Sage sets sights on Phase III; Receptos gets M&A interest;

@FierceBiotech: Index Ventures banks 650M euros for its new tech fund. Story | Follow @FierceBiotech

@JohnCFierce: Novartis steps in to help bankroll CRISPR-Cas9 pioneer Caribou. Article | Follow @JohnCFierce

@DamianFierce: Serious question: Is the $SRPT hold muzak an instrumental of "I'm all out of love / I'm so lost without you?" | Follow @DamianFierce

> After a positive meeting with the FDA, Sage Therapeutics ($SAGE) has designed a Phase III program for its top prospect, and the biotech is planning to start enrollment in the middle of the year. More

> Receptos ($RCPT), seeking out a partner for its in-development multiple sclerosis treatment, is getting heavy interest from potential acquirers, according to Bloomberg. News

> South Korea's Celltrion says it plans to launch a biosimilar of Johnson & Johnson's ($JNJ) blockbuster Remicade by the end of this year. Story

> Biotech investor MPM Capital has recruited longtime Novartis ($NVS) buyout director Tony Rosenberg to serve as a managing director, tapping his expertise for its portfolio companies. News

Medical Device News

@FierceMedDev: Japanese researchers study carbon nanotubes with drug delivery applications. FierceDrugDelivery story | Follow @FierceMedDev

@StacyALawrence: ICYMI: App enabling iPhone to function as hearing aid launched. Article | Follow @StacyALawrence

@VarunSaxena2: Pilot program deploying COPD Navigator app launched with participation of Mount Sinai hospital. Story | Follow @VarunSaxena2

@EmilyWFierce: Check out this week's edition of FierceLifeSci here, feat. $SHPG, $NVO, $PHG and a #FierceMadness update. Issue | Follow @EmilyWFierce

> Boston Scientific buys endoscopic, ultrasound pancreatic treatment startup for $75M+. Article

> Israeli scientist developing novel wound-closing laser. Item

> Medtronic tries again in renal denervation after previous trial failure. More

Pharma News

@FiercePharma: Texas Tech scientists discover that antibiotic-resistant bugs from cattle lots are airborne. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Actavis execs up for $101M in merger-related bonuses, if investors approve. Story | Follow @CarlyHFierce

> BMJ: Novartis tried to 'scupper' trials to protect Lucentis from cheap Avastin. More

> Watch out, pharma. Fitch says the M&A party could come with a hangover. Story

CRO News

> Piramal sells its CRO division to India's Indoco. Item

> WuXi and AstraZeneca roll toward Chinese approval with an arthritis drug. More

> Quintiles and Quest team up for lab testing with $575M JV. Report

> PPD's X-Chem flips some potential drugs to partner Navitor. Story

> Parexel buys an Indian CRO with an eye on drug safety. Article

Vaccines News

> Pfizer pulls vaccines sales business out of China. More

> Analysts: GSK shingles vaccine could steal market share from Merck's Zostavax. Story

> Sanofi, Merck win EMA nod for Gardasil 9. News

> GlaxoSmithKline and Merck Ebola vaccines succeed in Phase II Liberian trials. More

> GSK finally seals U.K. Bexsero deal for £20 per dose. Article

Pharma Manufacturing News

> Drug distributor goes 'Google' style with new facility. Article

> Catalent wraps another Asia-Pacific deal with Pharmapak buy. More

> Biocon's Syngene to build a plant in India. Story

> IPCA Labs' CRO in U.K. adding API space. Item

> Doctor to pay $2M, pleads guilty to dispensing foreign cancer drugs. Article

Pharma Asia News

> Infinity pulls trigger on Takeda oncology candidate option. More

> Takeda looks to settle thousands of Actos U.S. lawsuits for $2B. Article

> HK's Sihuan in partnership with Covance on drug development. Item

> India's Dr Reddy's snaps up some UCB brands in South Asia for $128.3M. Story

> Neurocrine and Mitsubishi Tanabe in license deal on Huntington's disease candidate. Report

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.